Xsphera Biosciences leverages 3D cell culture models and high-throughput screening to accelerate the identification and development of novel therapeutics. They integrate advanced cell biology with AI algorithms to predict drug efficacy and toxicity more accurately. By mimicking human biology in 3D, they aim to improve the success rate of oncology drug candidates in clinical trials. They provide services through their human tissue-based platform to test efficacy of various cancer therapeutics. Combined with Xsphera’s AI-powered analytics platform, they can identify drug mechanism of action, as well as resistance. Their approach holds promise for advancing precision medicine and addressing critical unmet needs in healthcare through transformative scientific research and technological innovation.

Xsphera Biosciences


              MarketsandMarkets Conferences
            

If you're attending BioKorea in Seoul this May, I invite you to connect with Kazu Ishikawa, our Vice President of Business Development. This event presents a valuable opportunity to explore how our platform can overcome the limitations of current preclinical testing. We are eager to schedule an introductory meeting to discuss potential collaborations that could enhance your oncology drug development initiatives. Please feel free to reach out through the partnering system or directly via email at kazu@xspherabio.com.

#biokorea2024 #biokorea #xsphera #drugdiscovery #PDOTS ##tumormicroenvironment #spheroids #preclinical #oncology #immuneoncology #cancer

Great to see patient-derived tumor models like #PDOTS being highlighted at SITC 2024! At Xsphera Biosciences, we’re proud to advance this space with our ex vivo platform, helping bridge the gap between preclinical models and human trials in immunotherapy.

Cell therapy translational research platforms are limited. Xsphera Biosciences is excited to introduce XspheraCT, a purpose built translational research program that leverages the microfluidics, human tissue platform for cell therapy developers.
Using a diversity of in-house tools and fresh human tissue, XspheraCT allows developers of cancer cell therapy to better elucidate lead optimization, candidate profiling and patient stratification.
To demonstrate the power of XspheraCT, our team has created a white paper that describes the necessity for more advanced approaches in cell therapy translational research. We also demonstrate our proof of concept and published, peer-reviewed evidences in human tumor samples.

Click the link below to access the white paper, peruse our website offerings and reach out to the team at sales@xspherabio.com. 
https://lnkd.in/gbHCAdnW

We look forward to helping you develop your cell therapy program!

#celltherapy #oncology #cancer #PDOTS #TME #tumormicroenvironment
#immunooncology #solidtumor

 Xsphera Biosciences and NEX-I Collaborate to Advance Oncology Drug Research 

Heading to Bio2024 in San Diego? Don’t miss the chance to connect with Kazu Ishikawa, our VP of Business Development! This event is a fantastic opportunity to discover how our platform can revolutionize preclinical testing. We’re eager to discuss potential collaborations to advance your oncology drug development. Reach out through the partnering system or directly at kazu@xspherabio.com. Let’s make progress together!

#BIO2024 #xsphera #drugdiscovery #PDOTS ##tumormicroenvironment #spheroids #preclinical #oncology #immuneoncology #cancer


              AACR-2024-NMC-FINAL.pdf
            

Radiobiological effects of wound fluid on breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic culture - Nature.com

Xsphera Biosciences and NEX-I Collaborate to Advance Oncology Drug Research

Login

 Xsphera Biosciences and NEX-I Collaborate To Advance Oncology Drug Research 


              Finding Effective CAR Drivers Using Ex Vivo Efficacy Models for Successful Cell Therapies
            

Dr. Aaron Goldman, Faculty and Instructor in Medicine at Harvard Medical School and Translational Research Process Advisor at Xsphera Biosciences, will be presenting at the webinar organized by Charles River Laboratories.
Don't miss this opportunity to learn about Xsphera ex vivo platform.

We invite you to visit our poster on the collaborative study with Nomocan Pharmaceuticals at the AACR 2024 in San Diego.

Learn about the advantages of MDOTS (Mouse-Derived Organotypic Tumor Spheroids) and PDOTS ( Patient-Derived Organotypic Tumor Spheroids ) in advancing drug development.
Our study highlights their roles in demonstrating drug efficacy and mechanism of action (MoA).

The poster will be on April 8 from 1:30 AM to 5:00 PM.
Michael Perricone will be available at the conference venue to connect with attendees interested in learning more about our platform.

Advanced ex vivo platform for drug response analysis: Evaluating the potent effects of NMC-521 mAb on mouse-and patient-derived organotypic tumor spheroids

#AACR #AACR2024 #PDOTS #MDOTS #geneexpression #Immunecontexture #solidtumors #oncology #cancer #tumormicroenvironment #spheroids #NSCLC

Excited to present new cell therapy data from our lab at the upcoming Next-Gen Immuno-Oncology Conference in Boston, June 20-21. I will be sharing unpublished findings that show candidate selection profiling in a new translational research platform that leverages human tumor tissue, endogenous immune cells and microfluidics. We have been able to link these data together with patient stratification to potentially predict responsive patient populations in later phase trials. The work I'll present is in collaboration with our industry partner, Xsphera Biosciences Inc. An exciting partnership that has been transformative for studying cell therapy activity!

Would be great to see my network there!

Thanks to the organizers and Shagun Kochhar for giving me the opportunity to share these new data.  
https://lnkd.in/dmSTkRhe

Nanoliposomes as nonviral vectors in cancer gene therapy - Yildiz - 2024 - MedComm - Wiley Online Library


      
      Xsphera Biosciences
    

Xsphera Biosciences

Business:

About: